Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder

2014-08-27 03:52:51 | BioPortfolio



The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD). A secondary objective is to characterize the safety and tolerability of utilizing quetiapine in patients with Borderline Personality Disorder.


Investigator initiated, 6-week, non-placebo controlled, non-randomized, open-label, single drug, single-center, medication trial.


Volunteers (n = 15) diagnosed with Borderline Personality Disorder using the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).


Subjects with Borderline Personality Disorder are washed out of all other medications. The subjects are then given the study drug at a dose within the drug's known therapeutic range.


Study Design: A six week, open-label, flexible dosing study using quetiapine. Subjects who qualify at Screening will then proceed to the baseline visit. If all inclusion and exclusion criteria are met, subjects will be administered quetiapine at the baseline visit. Enrollment will be 15 subjects. Enrollment is expected to last for a 6 month period.

Study Flow Sheet

Duration of Study and Visit Schedule. The subjects will have visits at the following intervals:

- Screening (Day -1 to -14)

- Visit 1 (Baseline)

- Visit 2 (Week 1)

- Visit 3 (Week 2)

- Visit 4 (Week 3)

- Visit 5 (Week 4)

- Visit 6 (Week 5)

- Visit 7 (Week 6)

Screening visit (Day -1 to -14): The following procedures will be performed:

1. Review of Inclusion and Exclusion criteria

2. Informed consent: Subject will be enrolled after signing an IRB approved informed consent. A signed copy will be given to the subject.

3. Review of Concomitant Medications

4. Medical/Disease History & Physical Exam, Vital Signs: The subject will have a H&P administered by an investigator. Weight, TPR, BP will be assessed. This will be done in Family medicine by Dr. Robert Hudrick, DO or Dr. Andrea Woll, DO.

5. A 12 Lead EKG will be done in Family medicine by Dr. Robert Hudrick, DO or Dr. Andrea Woll, DO.

6. Diagnostic Interview and Psychological Testing: Mental status will be conducted by the investigator and a SCID I and SCID II psychological test will be administered for screening and the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), Buss-Durkee Hostility Inventory (BDHI), Global Assessment of Functioning (GAF), Symptom Checklist 90 (SCL-90-R) and the Clinical Global Impression Scale (CGI) for severity of illness (Global Improvement and Efficacy not rated) will be utilized to measure the efficacy of quetiapine in this disorder.

7. Lab Parameters: Clinical laboratory samples will be collected and tests will be performed at Kennedy Health System Cherry Hill, NJ. They will be as follows:

A. Comprehensive Metabolic Panel

- albumin

- total bilirubin

- calcium

- carbon dioxide

- chloride

- creatinine

- glucose

- alkaline phosphatase

- potassium

- total protein

- sodium



- urea nitrogen (BUN)

B. Urine Drug Screen

- amphetamines

- barbiturates

- benzo

- cocaine

- opiate


- cannabinoids

C. Urine HCG in women


E. CBC/Differential

F. Electrocardiogram: EKG will screen for heart disease and arrhythmias

8. Subjects who have abnormal laboratory results will be discontinued from the study.

Visit 1 (Baseline).

Review of the following:

- Lab work

- Adverse Events

- Concomitant Medications

- Inclusion and Exclusion Criteria

- Beck Anxiety Inventory (BAI)

- Beck Depression Inventory ( BDI-II)

- Buss-Durkee Hostility Inventory (BDHI)

- Global Assessment of Functioning (GAF)

- Symptom Checklist 90 (SCL-90-R)

- Clinical Global Impression Scale (CGI) for severity of illness (Global Improvement and Efficacy not rated)

- Abnormal Involuntary Movement Scale (AIMS)

- Simpson-Angus Scale

Study Medication:

The investigator completes all evaluations and determines the medication dosage.

The study coordinator will then dispense the appropriate number of quetiapine tablets.

Visit 2 (Week 1); Visit 3 (Week 2); Visit 4 (Week 3); Visit 5 (Week 4); Visit 6 (Week 5).

Scales that will be used to assess positive change and medication safety during these visits are:

Scales (in alphabetical order):

- Abnormal Involuntary Movement Scale (AIMS)

- Beck Anxiety Inventory

- Beck Depression Inventory

- Buss-Durkee Hostility Inventory (BDHI)

- Clinical Global Impression (CGI)

- Global Assessment of Functioning GAF

- Simpson-Angus Scale

Inclusion Criteria:

To be considered for inclusion in this study subject must:

- Provide written informed consent before beginning any study related activities

- Be between age 18 and 55 years

- Be able to speak, read and write English and follow simple instructions for completing self-rated scales

- Meet DSM-IV criteria for BPD as assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). Those items screened positive by the subject on the Personality questionnaire will be further evaluated by pertinent subsections of the SKID-II.

Concomitant Therapy

Antipsychotic agents other than quetiapine will not be allowed during the study period. Patients who are taking other antipsychotic medication will require at least a three day washout period prior to the baseline visit.

Patients on anticonvulsants, lithium and benzodiazepines will be allowed to enter the study if they have been on the same dose of these agents for three months prior to the baseline visit

How Will the Study Be Analyzed

Laboratory Studies: Studies will be done at baseline and will screen for liver disease, kidney disease, electrolyte imbalance, thyroid or parathyroid dysfunction, respiratory acidosis or alkalosis, anemia, adequate blood cell and platelet count, pregnancy, and presence of illegal drugs. Any subjects with significant laboratory abnormalities will be excluded from the study.

Adverse Events: Subjects will be screened for the following side effects of quetiapine which are dizziness (10%), postural hypotension (7%), dry mouth (7%), and dyspepsia (6%), tachycardia (7%) and somnolence (18%). Patients will be also be monitored for other rare events including seizures, tardive dyskinesia, and neuroleptic malignant syndrome (NMS). Other less common side effects (> 1%) include headache (19% vs placebo 17%), asthenia (3% vs 2%), abdominal pain (3% vs 1%), back pain (2% vs 1%), fever (2% vs 1%), constipation (9% vs 5%),w eight gain (2% vs 0%), rash (4% vs 3%), rhinitis (3% vs 1%), and ear pain (1% vs 0%).

Data Analysis

The following will be reported and statistically analyzed:

- Number of patients who begin and complete the study (maximum n = 15).

- Patients who dropout of the study or are terminated with reasons.

- Demographic characteristics of the patients.

- Number of patients who had personality disorders in addition to Borderline Personality Disorder.

- The final average dose of quetiapine.

- The total score and percentage change of each scale and subscale utilized in the study and whether there was a statistically significant increase or reduction during the period of quetiapine administration.

- Movement Disorder side effects as assessed by the Abnormal Involuntary Movement Scale and the Simpson-Angus Scale and whether there was a statistically significant increase or reduction during the period of quetiapine administration.

- The number and percentage of adverse events that occurred during the period of quetiapine administration.

- The number and percentage of any abnormal laboratory results that occurred during the period of quetiapine administration.

After completion of data collection, the data will be analyzed to determine appropriate parametric analyses. As the N for this study will be 15, a T-test analysis may be applicable if the data permit. We anticipate a preliminary demonstration of treatment effect. Individual weekly scores will serve as dependent variables which lend themselves to a one-way analysis to demonstrate difference between baseline and 6 weeks of active treatment. If our data permit, a two-way T-test will also be employed to demonstrate statistically significant differences in treatment effect. As our data will likely require the utilization of multiple two-way analyses, our data will be Bonferroni corrected in order to adjust for the possibility of false positive (type II) errors. Other parametric analyses will be employed as the data warrant.

Study Design

Allocation: Non-Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Borderline Personality Disorder


Quetiapine Fumarate


University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry
Cherry Hill
New Jersey
United States




University of Medicine and Dentistry New Jersey

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:52:51-0400

Clinical Trials [892 Associated Clinical Trials listed on BioPortfolio]

Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far a...

Effectiveness of the Iconic Therapy for Borderline Personality Disorder Symptoms

Borderline personality disorder (BPD) is the most prevalent personality disorder in young community population whose most severe complication is suicide. Pharmacotherapy should not be used...

Naltrexone in Borderline Personality Disorder

The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to ...

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, ...

PubMed Articles [4887 Associated PubMed Articles listed on BioPortfolio]

Determining if Borderline Personality Disorder and Bipolar Disorder Are Alternative Expressions of the Same Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions.

To examine whether bipolar disorder and borderline personality disorder represent 2 different disorders or alternative manifestations of the same disorder.

Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism.

The article aims to examine trends in the pharmacological treatment of borderline personality disorder (BPD) and shed more light on the attendant controversies.

Suicide attempts and self-injurious behaviours in adolescent and adult patients with borderline personality disorder.

Prevalence data on self-mutilation and suicide attempts for adolescent borderline personality disorder (BPD) are currently not available. The purpose of this paper was to determine the frequency and m...

Borderline Personality Disorder and Mental Health Care Utilization: The Role of Self-Harm.

The current study examined the associations for borderline personality disorder (BPD) and a specific trait of the disorder, self-harm, with mental health care utilization. Our sample consisted of 145 ...

State-Dependent Cross-Brain Information Flow in Borderline Personality Disorder.

Although borderline personality disorder (BPD)-one of the most common, burdensome, and costly psychiatric conditions-is characterized by repeated interpersonal conflict and instable relationships, the...

Medical and Biotech [MESH] Definitions

A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

A dissociative disorder in which the individual adopts two or more distinct personalities. Each personality is a fully integrated and complex unit with memories, behavior patterns and social friendships. Transition from one personality to another is sudden.

A personality disorder whose essential feature is a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood. The individual must be at least age 18 and must have a history of some symptoms of CONDUCT DISORDER before age 15. (From DSM-IV, 1994)

A personality disorder characterized by the avoidance of accepting deserved blame and an unwarranted view of others as malevolent. The latter is expressed as suspiciousness, hypersensitivity, and mistrust.

More From BioPortfolio on "Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...